GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (NAS:PPBT) » Definitions » Debt-to-Equity

Purple Biotech (Purple Biotech) Debt-to-Equity : 0.01 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Purple Biotech Debt-to-Equity?

Purple Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.19 Mil. Purple Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.16 Mil. Purple Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $34.21 Mil. Purple Biotech's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Purple Biotech's Debt-to-Equity or its related term are showing as below:

PPBT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.01   Max: 0.38
Current: 0.01

During the past 11 years, the highest Debt-to-Equity Ratio of Purple Biotech was 0.38. The lowest was 0.01. And the median was 0.01.

PPBT's Debt-to-Equity is ranked better than
99.91% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs PPBT: 0.01

Purple Biotech Debt-to-Equity Historical Data

The historical data trend for Purple Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Debt-to-Equity Chart

Purple Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 0.01 0.01 0.01

Purple Biotech Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Competitive Comparison of Purple Biotech's Debt-to-Equity

For the Biotechnology subindustry, Purple Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Purple Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Purple Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Purple Biotech's Debt-to-Equity falls into.



Purple Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Purple Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Purple Biotech's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Purple Biotech  (NAS:PPBT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Purple Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Purple Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Purple Biotech (Purple Biotech) Business Description

Traded in Other Exchanges
Address
4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.